Accent Therapeutics


    Accent is undertaking the systematic chemical biology and drug discovery efforts required to characterize and target compelling RNA modifications as new approaches to precision cancer therapeutics. The Accent team is uniquely qualified to practice SMD discovery and development in the area of RMP inhibitors, building on a track record of success in delivering novel SMDs to the clinic. Among the executive team, scientific advisory board and board of directors, the Accent team has previously delivered more than 200 SMDs to the clinic and, collectively, have contributed to more than 40 approved drugs that are in clinical use today.